

From: [Nicole Capobianco](#)
To: [AGO - High Cost Prescription Drugs](#)
Cc: [SPTR,Aucta](#)
Subject: Aucta - Notice of New Drug Introduction Pursuant to 18 V.S.A § 4637(c)
Date: Wednesday, March 13, 2024 9:35:55 AM
Attachments: [image001.jpg](#)
[image002.png](#)
[image003.png](#)
[image004.png](#)
[image005.png](#)

Some people who received this message don't often get email from nicole.capobianco@rldatixlifesciences.com.
[Learn why this is important](#)

EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.

To the Office of the Attorney General:

Pursuant to 18 V.S.A § 4637(c), Aucta Pharmaceuticals provides the following report for Motpoly XR, subsequent to the previous notice submitted on February 13/2024.

NDC	Product Name	Product Description
73289006302	Motpoly XR™	Motpoly XR™ 100 mg, 60
73289006402	Motpoly XR™	Motpoly XR™ 150 mg, 60
73289006502	Motpoly XR™	Motpoly XR™ 200 mg, 60

Marketing and Pricing Plans

Pricing based on similar marketed brand anti-seizure medications.

Estimated Patient Volume

900

Breakthrough Therapy/Priority Review

No

Acquisition Date and Price

NA

Please reach out if you have any questions.

Regards,

Nicole Capobianco on behalf of

Pat Santangelo

Aucta Pharmaceuticals Inc.

732.640.0030

Nicole Capobianco | Senior Commercial Analyst

T: + 732-369-3988 | E: Nicole.Capobianco@rldatixlifesciences.com

